These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19301646)

  • 21. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases.
    Takahashi Y; Nishikawa M; Kobayashi N; Takakura Y
    J Control Release; 2005 Jul; 105(3):332-43. PubMed ID: 15936841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW; Davis ME
    Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.
    Ofek P; Fischer W; Calderón M; Haag R; Satchi-Fainaro R
    FASEB J; 2010 Sep; 24(9):3122-34. PubMed ID: 20385622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacterial delivery of RNAi effectors: transkingdom RNAi.
    Lage H; Krühn A
    J Vis Exp; 2010 Aug; (42):. PubMed ID: 20811323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of interferon response in animals to naked siRNAs.
    Heidel JD; Hu S; Liu XF; Triche TJ; Davis ME
    Nat Biotechnol; 2004 Dec; 22(12):1579-82. PubMed ID: 15558046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery of RNA interference to peripheral neurons in vivo using herpes simplex virus.
    Anesti AM
    Methods Mol Biol; 2010; 617():347-61. PubMed ID: 20336434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
    Malek A; Tchernitsa O
    Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion.
    Zhao HF; L'Abbé D; Jolicoeur N; Wu M; Li Z; Yu Z; Shen SH
    Nat Methods; 2005 Dec; 2(12):967-73. PubMed ID: 16299483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells.
    Park WS; Hayafune M; Miyano-Kurosaki N; Takaku H
    Gene Ther; 2003 Nov; 10(24):2046-50. PubMed ID: 14566364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery of small interfering RNA with a synthetic collagen poly(Pro-Hyp-Gly) for gene silencing in vitro and in vivo.
    Adachi T; Kawakami E; Ishimaru N; Ochiya T; Hayashi Y; Ohuchi H; Tanihara M; Tanaka E; Noji S
    Dev Growth Differ; 2010 Oct; 52(8):693-9. PubMed ID: 20874713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing.
    Luo Q; Kang Q; Song WX; Luu HH; Luo X; An N; Luo J; Deng ZL; Jiang W; Yin H; Chen J; Sharff KA; Tang N; Bennett E; Haydon RC; He TC
    Gene; 2007 Jun; 395(1-2):160-9. PubMed ID: 17449199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of hairpin-based RNAi vectors for biological and therapeutic application.
    Boudreau RL; Davidson BL
    Methods Enzymol; 2012; 507():275-96. PubMed ID: 22365779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.